Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Ltd (OKYO) is a clinical-stage biopharmaceutical company pioneering novel therapies for ocular inflammatory conditions and neuropathic pain. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory developments, and strategic partnerships.
Investors and researchers will find timely updates on OKYO's lead candidate OK-101, a patented chemerin analog targeting dry eye disease and corneal neuropathic pain. All content is sourced directly from company filings and press releases to ensure accuracy.
The news archive includes updates on: Phase 2 clinical trial progress, intellectual property milestones, research collaborations, and regulatory pathway developments. Content is organized chronologically for tracking therapeutic advancement timelines.
Bookmark this page for streamlined access to OKYO's latest scientific and corporate developments. Check regularly for updates on ocular therapeutic innovations with potential to address unmet medical needs in global markets.
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO) has announced its interim results for the six months ending September 30, 2022. The company has achieved FDA IND clearance for its Phase 2 trial of OK-101 to treat Dry Eye Disease (DED), expected to begin in Q1 2023. Financially, OKYO reported total assets of £1.6 million and cash of £0.6 million, with a comprehensive loss of £4.6 million. The company has halted further development of OK-201 to focus resources on OK-101.
OKYO Pharma Limited has received FDA clearance to start a Phase 2 clinical trial for OK-101, a treatment for Dry Eye Disease (DED). This first-in-human study will assess both efficacy endpoints relating to the signs and symptoms of DED. The trial is set to begin in Q1 2023, aiming to demonstrate OK-101's potential as a novel treatment option for patients inadequately addressed by existing medications. The company emphasizes that success in this trial could expedite the filing for a new drug application (NDA) with the FDA.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced its participation in the Biotech Showcase in San Francisco from January 9-11, 2023. The company focuses on developing OK-101 to treat dry eye disease, addressing significant unmet needs in this multi-billion-dollar market. CEO Dr. Gary Jacob and other executives will present and hold 1x1 institutional investor meetings during the event. Attendees can schedule meetings online. The event highlights OKYO's commitment to innovation in treating inflammatory dry eye diseases.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) has filed a Form F-1 registration statement with the SEC for a secondary public offering of its American Depositary Shares (ADSs). Each ADS will represent 65 ordinary shares. The offering's size and price are yet to be determined and depend on market conditions. This offering, approved by shareholders at the September 2022 AGM, will allow OKYO's shares to continue trading on the LSE and NASDAQ. ThinkEquity is the sole bookrunning manager, and the offering will not be available in the EEA or UK to the public.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) appointed PKF Littlejohn LLP as its new independent auditor effective immediately. The board approved PKF for the financial year ending March 31, 2023, with re-appointment subject to shareholder approval at the next AGM in 2023. The previous auditor, Mazars LLP, confirmed no matters for the Company’s members or creditors. OKYO thanks Mazars for their service. This announcement contains inside information under UK market regulations.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) has awarded Chief Scientific Officer Raj Patil 5,000,000 options with an exercise price of 6.25 pence per share, recognizing his contribution to the recent IND filing for OK-101, aimed at treating dry eye disease. The options vest immediately and have a five-year lifespan. This move highlights the company's advancement in developing therapies for the significant unmet needs in the dry eye market, which is valued in the billions. The announcement complies with UK MAR regulations.
OKYO Pharma Ltd (NASDAQ: OKYO) announced a Key Opinion Leader webinar on November 14, 2022, regarding its potential treatment, OK-101, for inflammatory dry eye disease. The event features KOL Pedram Hamrah, MD, discussing preclinical data on OK-101's efficacy. The company aims to address a significant market need in dry eye therapies and will provide updates on its Phase 2 trial for OK-101, a lipid-conjugated peptide targeting ocular pain and inflammation.
OKYO Pharma Limited (NASDAQ: OKYO) announced its CEO, Dr. Gary Jacob, will be featured on The RedChip Money Report on Bloomberg TV on September 10, 2022. The interview will cover the company's NASDAQ listing, plans for a Phase 2 study for Dry Eye Disease, and expectations for top-line data. This access expands OKYO's visibility as it operates in the biotechnology sector, focusing on new treatments for inflammatory dry eye diseases and ocular pain.
OKYO Pharma Limited (NASDAQ: OKYO) announced an upcoming interview with CEO Dr. Gary Jacob on the RedChip Money Report airing on Bloomberg TV on September 10, 2022, at 7 p.m. ET. The interview will cover the company's NASDAQ listing and plans for a Phase 2 study for Dry Eye Disease, including anticipated top-line data. OKYO focuses on developing novel treatments for inflammatory dry eye diseases and chronic pain, and is listed on both NASDAQ and the London Stock Exchange.
On September 7, 2022, OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that all resolutions at its Annual General Meeting were successfully passed. The voting results showed overwhelming support, with key resolutions such as the approval of the report and accounts receiving 99.99852% approval. Shareholders, totaling 1,415,040,468 ordinary shares, participated actively in the voting process. The resolutions included the re-election of directors and the appointment of auditors, reflecting strong governance practices and shareholder confidence in the company's direction.
FAQ
What is the current stock price of OKYO PHARMA (OKYO)?
What is the market cap of OKYO PHARMA (OKYO)?
